Inclusion Criteria:

          1. Phase I: Patients with advanced/metastatic solid tumors, with measurable or
             unmeasurable disease as determined by Response Evaluation Criteria in Solid Tumors
             (RECIST) version 1.1

          2. Phase I: Patients with a site of disease amenable to biopsy, and willing to undergo a
             new tumor biopsy at screening, and during treatment.

          3. Phase II: Patients with advanced/metastatic/recurrent isocitrate dehydrogenase (IDH)
             wild-type glioblastoma, with at least one measurable lesion as determined by RANO

        Other protocol defined inclusion criteria may apply

        Exclusion Criteria:

          1. History of severe hypersensitivity reactions to monoclonal antibodies.

          2. Impaired cardiac function or clinically significant cardiac disease.

          3. Active autoimmune disease or a documented history of autoimmune disease.

          4. Systemic steroid therapy or any immunosuppressive therapy

          5. Use of any vaccines against infectious diseases within 4 weeks of initiation of study
             treatment.

          6. Patient receiving treatment with medications that either strong inducers or inhibitors
             of CYP2C8 or CYP3A4/5, or patients receiving medication that prohibits proton pump
             inhibitors and that cannot be discontinued at least 1 week prior to start of treatment
             and for the duration of the study.

        Other protocol defined exclusion criteria may apply.